{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T22:33:56Z","timestamp":1718577236580},"reference-count":54,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.plefa.2010.12.001","type":"journal-article","created":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T09:28:04Z","timestamp":1294306084000},"page":"79-83","source":"Crossref","is-referenced-by-count":9,"title":["Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study"],"prefix":"10.1016","volume":"84","author":[{"given":"R.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fleet-Michaliszyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Condray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.K.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Keshavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2010.12.001_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/0003-066X.60.3.229","article-title":"The primacy of cognition in schizophrenia","volume":"60","author":"Heinrichs","year":"2005","journal-title":"Am. Psychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/schbul\/10.2.160","article-title":"Information processing and attentional functioning in the developmental course of schizophrenic disorders","volume":"10","author":"Nuechterlein","year":"1984","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.plefa.2010.12.001_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1176\/jnp.6.4.348","article-title":"Working memory dysfunction in schizophrenia","volume":"6","author":"Goldman-Rakic","year":"1994","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.plefa.2010.12.001_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1037\/0021-843X.105.1.81","article-title":"Language production and thought disorder in schizophrenia","volume":"105","author":"Barch","year":"1996","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0006-3223(95)00378-T","article-title":"Language comprehension in schizophrenia: trait or state indicator?","volume":"38","author":"Condray","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.biopsych.2005.09.005","article-title":"Generalized and specific neurocognitive deficits in prodromal schizophrenia","volume":"59","author":"Lencz","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.psc.2005.05.004","article-title":"Cognition in schizophrenia: impairments, determinants, and functional importance","volume":"28","author":"Bowie","year":"2005","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.plefa.2010.12.001_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1037\/0894-4105.19.6.778","article-title":"No, it is not possible to be schizophrenic yet neuropsychologically normal","volume":"19","author":"Wilk","year":"2005","journal-title":"Neuropsychology"},{"key":"10.1016\/j.plefa.2010.12.001_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1176\/appi.ajp.163.3.411","article-title":"Barriers to employment for people with schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.eurpsy.2005.02.006","article-title":"Patient outcomes in schizophrenia II: the impact of cognition","volume":"20","author":"Hofer","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib11","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.socscimed.2005.08.003","article-title":"Social network in long-term diseases: a comparative study in relatives of persons with schizophrenia and physical illnesses versus a sample from the general population","volume":"62","author":"Magliano","year":"2006","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.plefa.2010.12.001_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-9964(97)00010-8","article-title":"The functional significance of symptomatology and cognitive function in schizophrenia","volume":"25","author":"Velligan","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.schres.2005.03.001","article-title":"Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program","volume":"77","author":"Prouteau","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1076\/jcen.26.2.153.28079","article-title":"Working memory performance in poor outcome schizophrenia: relationship to age and executive functioning","volume":"26","author":"McGurk","year":"2004","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00005053-200211000-00001","article-title":"Executive function in schizophrenia: is it linked to psychosis and poor life functioning?","volume":"190","author":"Reed","year":"2002","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.plefa.2010.12.001_bib17","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2165\/00003495-200666110-00004","article-title":"Pharmacological approaches to the management of cognitive dysfunction in schizophrenia","volume":"66","author":"Harvey","year":"2006","journal-title":"Drugs"},{"issue":"Suppl A","key":"10.1016\/j.plefa.2010.12.001_bib18","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.clinthera.2005.07.015","article-title":"Treatment of cognitive dysfunction in schizophrenia","volume":"27","author":"Peuskens","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.plefa.2010.12.001_bib19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","article-title":"Molecular targets for treating cognitive dysfunction in schizophrenia","volume":"33","author":"Gray","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.plefa.2010.12.001_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.plefa.2006.07.003","article-title":"The emerging role of omega-3 fatty acids in psychiatry","volume":"75","author":"McNamara","year":"2006","journal-title":"Prostaglandins Leukotrienes Essent. Fatty Acids"},{"key":"10.1016\/j.plefa.2010.12.001_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mnfr.200900201","article-title":"Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function","volume":"54","author":"Heinrichs","year":"2010","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/(SICI)1097-4547(19990615)56:6<565::AID-JNR2>3.0.CO;2-H","article-title":"Essential fatty acids are mediators of brain biochemistry and cognitive functions","volume":"56","author":"Yehuda","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib23","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1100\/tsw.2002.870","article-title":"Membrane pathology in schizophrenia: implication for arachidonic acid signaling","volume":"2","author":"Yao","year":"2002","journal-title":"Sci.World J."},{"key":"10.1016\/j.plefa.2010.12.001_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.plefa.2010.07.001","article-title":"Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia","author":"Sethom","year":"2010","journal-title":"Prostaglandins Leukotrienes Essent. Fatty Acids"},{"key":"10.1016\/j.plefa.2010.12.001_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0920-9964(94)90014-0","article-title":"Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity","volume":"11","author":"Yao","year":"1994","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/oxfordjournals.schbul.a007140","article-title":"Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline","volume":"30","author":"Reddy","year":"2004","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.plefa.2010.12.001_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0920-9964(99)00095-X","article-title":"Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients","volume":"42","author":"Yao","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0006-3223(91)90235-E","article-title":"Fatty acid levels in the brains of schizophrenics and normal controls","volume":"30","author":"Horrobin","year":"1991","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2006.11.027","article-title":"Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications","volume":"91","author":"McNamara","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.plefa.2003.08.010","article-title":"Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment","volume":"69","author":"Evans","year":"2003","journal-title":"Prostaglandins Leukotrienes Essent. Fatty Acids"},{"key":"10.1016\/j.plefa.2010.12.001_bib31","first-page":"CD001257","article-title":"Polyunsaturated fatty acid supplementation for schizophrenia","volume":"3","author":"Joy","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.plefa.2010.12.001_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3956(01)00048-6","article-title":"A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms","volume":"36","author":"Peet","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.plefa.2010.12.001_bib35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0920-9964(94)90045-0","article-title":"Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition","volume":"13","author":"Yao","year":"1994","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib37","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psychres.2007.06.029","article-title":"Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial","volume":"161","author":"Emsley","year":"2008","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib38","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1176\/appi.ajp.158.12.2071","article-title":"A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia","volume":"158","author":"Fenton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1076\/clin.13.3.283.1743","article-title":"Practice effects on commonly used measures of executive function across twelve months","volume":"13","author":"Basso","year":"1999","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1076\/clin.15.4.471.1883","article-title":"Practice effects on the Wisconsin card sorting test-64 card version across 12 months","volume":"15","author":"Basso","year":"2001","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0920-9964(97)00070-4","article-title":"Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases","volume":"26","author":"McGrath","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/arclin\/8.6.519","article-title":"Effects of repeated neuropsychological assessments","volume":"8","author":"McCaffrey","year":"1993","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib43","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/npp.2009.211","article-title":"Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies","volume":"35","author":"Goldberg","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.plefa.2010.12.001_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0920-9964(03)00213-5","article-title":"Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia","volume":"68","author":"Hill","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.plefa.2010.12.001_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1037\/0021-843X.109.3.534","article-title":"Learning and forgetting in schizophrenia","volume":"109","author":"Gold","year":"2000","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.plefa.2010.12.001_bib46","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib47","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/ajcn\/80.6.1650","article-title":"Cognitive aging, childhood intelligence, and the use of food supplements: possible involvement of n-3 fatty acids","volume":"80","author":"Whalley","year":"2004","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.plefa.2010.12.001_bib48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1440-1614.2001.01021.x","article-title":"Implications of lipid biology for the pathogenesis of schizophrenia","volume":"36","author":"Berger","year":"2002","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.plefa.2010.12.001_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.plefa.2008.11.006","article-title":"Gene and protein expression profiling of the fat-1 mouse brain","volume":"80","author":"Menesi","year":"2009","journal-title":"Prostaglandins Leukotrienes Essent. Fatty Acids"},{"key":"10.1016\/j.plefa.2010.12.001_bib50","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/sj.npp.1301628","article-title":"Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study","volume":"33","author":"Berger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.plefa.2010.12.001_bib51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0269881106067787","article-title":"Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder","volume":"21","author":"Frangou","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.plefa.2010.12.001_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainresbull.2006.10.020","article-title":"Ethyl\u2013EPA in Huntington disease: potentially relevant mechanism of action","volume":"72","author":"Murck","year":"2007","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.plefa.2010.12.001_bib53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jnutbio.2009.11.003","article-title":"Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance","volume":"21","author":"Su","year":"2010","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.plefa.2010.12.001_bib54","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2165\/00023210-200317150-00003","article-title":"Clinical potential of omega-3 fatty acids in the treatment of schizophrenia","volume":"17","author":"Emsley","year":"2003","journal-title":"CNS Drugs"}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327810001961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327810001961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T16:40:08Z","timestamp":1559925608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327810001961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":54,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0952327810001961"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2010.12.001","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}